PTX3 and stricture: While TNF-α or IL-6-receptor inhibitors therapy was reported to reduce the production of PTX3, reflecting vascular inflammation and progression in TAK patients [11], IL-6-receptor antibody improved neither vascular stenosis nor thickness nor PTX-3 level [32].